Zevenbergen Capital Investments LLC Has $74.13 Million Stock Position in Natera, Inc. $NTRA

Zevenbergen Capital Investments LLC lessened its stake in Natera, Inc. (NASDAQ:NTRA) by 18.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 323,571 shares of the medical research company’s stock after selling 70,994 shares during the quarter. Natera accounts for about 1.6% of Zevenbergen Capital Investments LLC’s investment portfolio, making the stock its 20th biggest holding. Zevenbergen Capital Investments LLC’s holdings in Natera were worth $74,127,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the company. Horizon Investments LLC bought a new stake in shares of Natera in the third quarter valued at about $32,000. Sound Income Strategies LLC raised its position in Natera by 95.7% in the 3rd quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock valued at $39,000 after buying an additional 110 shares during the last quarter. Quent Capital LLC bought a new stake in Natera in the 3rd quarter valued at approximately $46,000. Hilltop National Bank lifted its stake in Natera by 59.8% in the 3rd quarter. Hilltop National Bank now owns 310 shares of the medical research company’s stock valued at $50,000 after acquiring an additional 116 shares in the last quarter. Finally, N.E.W. Advisory Services LLC lifted its stake in Natera by 256.8% in the 2nd quarter. N.E.W. Advisory Services LLC now owns 314 shares of the medical research company’s stock valued at $53,000 after acquiring an additional 226 shares in the last quarter. Institutional investors own 99.90% of the company’s stock.

Analyst Upgrades and Downgrades

NTRA has been the subject of several research reports. Guggenheim raised their price target on shares of Natera from $230.00 to $270.00 and gave the stock a “buy” rating in a research note on Monday, January 5th. Wells Fargo & Company increased their target price on shares of Natera from $205.00 to $215.00 and gave the stock an “equal weight” rating in a report on Friday, February 27th. Barclays lifted their price target on shares of Natera from $230.00 to $270.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. BTIG Research increased their price objective on shares of Natera from $230.00 to $260.00 and gave the stock a “buy” rating in a research note on Friday, December 5th. Finally, Canaccord Genuity Group restated a “buy” rating on shares of Natera in a report on Monday, January 12th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $253.47.

Insiders Place Their Bets

In related news, insider John Fesko sold 17,806 shares of the business’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $234.74, for a total transaction of $4,179,780.44. Following the transaction, the insider directly owned 177,591 shares of the company’s stock, valued at approximately $41,687,711.34. The trade was a 9.11% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Solomon Moshkevich sold 23,205 shares of the stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $234.74, for a total value of $5,447,141.70. Following the completion of the sale, the insider owned 144,992 shares in the company, valued at approximately $34,035,422.08. This trade represents a 13.80% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 318,344 shares of company stock worth $74,091,416 in the last three months. 5.63% of the stock is owned by corporate insiders.

Natera Price Performance

Shares of NTRA opened at $186.84 on Tuesday. The firm has a 50-day moving average of $210.12 and a 200-day moving average of $208.74. Natera, Inc. has a one year low of $125.38 and a one year high of $256.36. The company has a market cap of $26.48 billion, a PE ratio of -122.12 and a beta of 1.65.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.81. Natera had a negative net margin of 9.03% and a negative return on equity of 15.28%. The company had revenue of $665.50 million for the quarter, compared to analysts’ expectations of $600.68 million. During the same period in the prior year, the firm earned ($0.41) EPS. Analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.